When the FDA issued its warning about a potential association between GLP-1 receptor agonists and thyroid C-cell tumors in 2023, it created significant concern among patients and providers. The warning was based on animal studies showing an increased incidence of thyroid C-cell adenomas and carcinomas in rodents exposed to semaglutide at high doses over extended periods. Understanding what this means in practical terms — and what it does not mean — is important for anyone on or considering GLP-1 therapy.
Understanding the connection between GLP-1 receptor agonists and thyroid health, including the medullary thyroid carcinoma warning and what monitoring is recommended.
Understanding Thyroid C-Cell Biology
The thyroid gland contains several distinct cell types, each with different functions. C-cells (also called parafollicular cells) produce calcitonin, a hormone involved in calcium metabolism. Medullary thyroid carcinoma (MTC) is a cancer that arises from C-cells, accounting for approximately 3-5% of all thyroid cancers.
GLP-1 receptors are expressed on thyroid C-cells, at least in rodents. Activation of these receptors appears to stimulate C-cell proliferation in animal models, which is the biological basis for the cancer concern. However, the receptor distribution and signaling pathways in human thyroid tissue may differ from those in rodents, and the clinical significance of this finding in humans remains an active area of investigation.
To date, large-scale human clinical trials and post-marketing surveillance have not demonstrated a clear causal link between GLP-1 receptor agonists and medullary thyroid carcinoma in humans. The FDA warning is based on preclinical data, and the agency acknowledges that the risk in humans has not been established. Nevertheless, the warning is taken seriously in clinical practice, and appropriate precautions are recommended.
The Calcitonin Connection
Calcitonin is the hormone produced by C-cells, and elevated serum calcitonin levels are a marker for C-cell activity or neoplasia. In the context of GLP-1 therapy, calcitonin monitoring has emerged as a practical clinical tool.
Several studies have shown that GLP-1 receptor agonists can cause mild, reversible elevations in serum calcitonin in some patients. In the vast majority of cases, these elevations are within the normal range and do not indicate pathology. However, persistent or significantly elevated calcitonin — particularly above 50-100 pg/mL — warrants further evaluation and may indicate C-cell hyperplasia or, more rarely, medullary thyroid carcinoma.
The key distinction is between a mild, stable elevation that is a pharmacological effect of the medication and a progressive elevation that suggests underlying pathology. Patients on long-term GLP-1 therapy should have baseline and periodic calcitonin measurements to establish this distinction.
